Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
15 evidence topics · 23 sources
Guideline recommendation to select systemic therapy by comorbidity and individual patient factors
“We recommend taking into account efficacy (see Figure 1, Figure 2, and summary of the Cochrane Review), safety (see drug chapters), comorbidities (see Table 1 and Table 2 in publication Part 2, and respective chapters in the long version), and individual patient factors when choosing a systemic treatment for moderate to severe psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Accordingly, individual recommendation strengths arise individually from the examination of each patient, taking the factors effectiveness, safety, comorbidity, and other individual patient factors into account.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity-guided selection: inflammatory bowel disease, diabetes, cancer history, and latent tuberculosis
“In patients with psoriasis and IBD, we recommend preferentially using approved targeted therapies with documented efficacy in these conditions:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest against the use of IL17 inhibitors in patients with inflammatory bowel disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If alternative treatments are available, we suggest prescribing alternatives to MTX in patients with type 2 diabetes (with concomitant metabolic syndrome and/or signs of liver damage).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients in remission of cancer for more than 5 years, we recommend selecting the most appropriate option for psoriasis treatment independent of the cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with latent TB infection, we recommend choosing one of the following options:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“acitretin, apremilast, ciclosporin, dimethyl fumarate, MTX, or phototherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest against the use of deucravacitinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in patients with latent TB infections unless there are no other suitable treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to lack of data concerning the reactivation risk” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Conditions that make a biologic class less suitable: decision aid
| Biologic class | Conditions listed in the decision aid |
|---|---|
| TNF inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab) | “Moderate or severe heart failure, multiple sclerosis (or other conditions affecting the nerves)” |
| IL-12/23 inhibitor (ustekinumab) | “No particular condition” |
| IL-17 inhibitors (bimekizumab, brodalumab, ixekizumab, secukinumab) | “Inflammatory bowel disease (e.g. Crohn disease or ulcerative colitis), recurrent candida infection (i.e. thrush)” |
Agent selection by comorbidity, special population, and phenotype: U.S. reviews
“Selection of the appropriate treatment modality has evolved substantially with the rapid expansion of available options that can be individualized based on patients' comorbidity profiles, extent of disease, prior therapeutic response, and treatment preferences.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This first article of a two-part series focuses on selecting systemic therapy for PsO patients with specific inflammatory comorbidities or a history of malignancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Choosing systemic therapy for psoriasis remains challenging in populations underrepresented in clinical trials, including pregnant and pediatric patients, patients with chronic infections, and those with difficult-to-treat phenotypes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Emphasis is placed on balancing efficacy, safety, monitoring burden, infection/reactivation risk, reproductive considerations, and disease phenotype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Body weight: overweight and early loss of biologic efficacy in severe psoriasis
“Among the 87 patients (mean [SD] age, 42.2 [12.5] years; 24 female patients and 63 male patients) included in the study, 16 (18.4%) had to switch to other biologics because of an early loss of therapeutic efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Having overweight (body mass index, >25) was the only clinically relevant factor (odds ratio, 17.3; 95% CI, 3.2-434.6; P = .009).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Body weight: exposure and dosing statements in biologic labels
Response across age, sex, race, body weight, baseline severity, and prior therapy subgroups: oral agent labels
Response across age, sex, race, body weight, and prior therapy subgroups: IL-17 and IL-23 inhibitor labels
Bimekizumab PASI 100 through 3 years by age, sex, weight, disease duration, severity, nail involvement, and prior biologic exposure
“Subgroups of patients with moderate to severe plaque psoriasis were defined by age, sex, weight, disease duration, disease severity, nail involvement (modified Nail Psoriasis Severity Index > 0), and prior biologic exposure, at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who received bimekizumab continuously for 3 years (N = 1107), PASI 100 response rates remained consistent across age (68.6% [40 to < 65 years]–73.7% [≥ 65 years]), sex (69.6% [male]–71.4% [female]), weight (63.4% [≥ 103.9 kg]–75.5% [< 74.3 kg]), disease duration (65.5% [≤ 5 years]–71.1% [> 20 years]), disease severity (67.7% [PASI 12 to < 15]–71.1% [PASI ≥ 20]), nail involvement (69.1% [yes]/71.3% [no]), and prior biologic exposure (71.7% [yes]/69.1% [no]; prior anti-TNF exposure 67.6% [yes]/70.6% [no]) subgroups; 95% CIs overlapped in all instances, indicating no meaningful differences between subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior biologic or apremilast exposure: deucravacitinib real-world response through 52 and 104 weeks
“Among the total 110 patients, 71 were apremilast‐naïve and 39 were apremilast‐experienced, while 95 were biologic‐naive and 15 were biologic‐experienced (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both in biologic naive and experienced patients, mean PASI scores continued to decrease from week 0 to week 52; however, the magnitude of decrease appeared higher in biologic‐naive patients: from 15.53 to 1.30 in biologic‐naive patients (91.6% reduction) versus from 7.78 to 3.30 (57.6% reduction) in biologic‐experienced patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We studied 131 patients with moderate-to-severe psoriasis who received deucravacitinib 6 mg/day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Week 104 achieving PASI 100 and absolute PASI ≤ 1 were higher in apremilast-naïve patients (15.4% and 53.8%) than in apremilast-experienced patients (0% and 25%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Week 104 achieving PASI 75, PASI 90, PASI 100, and absolute PASI ≤ 1 were higher in biologic-naïve patients (84.6%, 57.7%, 15.4%, and 53.8%) than in biologic-experienced patients (25%, 25%, 0%, and 25%, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prior apremilast nonresponse: deucravacitinib response in POETYK PSO-1 and PSO-2 through week 52
“Of 168 (PSO-1) and 254 (PSO-2) patients randomized to apremilast, 54 (32.1% [PSO-1]) and 111 (43.7% [PSO-2]) did not achieve PASI 50 (PSO-1) and PASI 75 (PSO-2) at Week 24 and were switched to deucravacitinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PASI 75 response rates improved from 0% at Week 24 to 46.3% (PSO-1) and 42.3% (PSO-2) at Week 52.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior systemic treatment status and the network meta-analysis
“Indeed, response to biologics is different depending on treatment status (systemic‐naïve or not).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, due to the limited number of studies available for some specific comparisons, subgroup analyses and meta‐regressions were not possible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Asian populations: deucravacitinib network meta-analysis estimates
“Evidence suggests the comparative efficacy of systemic therapies may be different in Asian versus White patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated PASI 75 and 90 (95% credible interval) response rates for deucravacitinib were estimated to be 66% (49%–80%) and 40% (24%–58%) in Asian populations, notably higher than placebo (6% [4%–9%] and 1% [0.8–2%]) and apremilast (24% [12%–40%] and 9% [4%–20%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No statistically significant difference was observed in PASI 75 and 90 responses between deucravacitinib and adalimumab, certolizumab pegol, infliximab, ustekinumab, and tildrakizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Japanese participants in POETYK PSO-1: week 16 and week 24 PASI 75
“This report describes efficacy and safety in Japanese patients from this study (N = 66) who were randomly assigned to treatment with deucravacitinib 6 mg once daily (n = 32), placebo (n = 17), or apremilast 30 mg twice daily (n = 17).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of Japanese patients achieving ≥75% reduction from baseline in PASI (PASI 75) score was numerically higher with deucravacitinib versus placebo and apremilast at Week 16 (78.1% vs. 11.8% and 23.5%, respectively) and versus apremilast at Week 24 (78.1% vs. 29.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy and safety of deucravacitinib in Japanese patients was consistent with those in the global population in POETYK PSO-1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prespecified efficacy and safety subgroups in the envudeucitinib phase 2 statistical analysis plan
“BSA involvement (10–20 %, > 20 %)” (opens the source at this quote in a new tab)
“PASI (≤ 20, > 20)” (opens the source at this quote in a new tab)
“Race (White, Non-white)” (opens the source at this quote in a new tab)
“Baseline weight category (<90 kg, ≥ 90 kg)” (opens the source at this quote in a new tab)
“Baseline BMI category (<30 kg/m2, ≥30 kg/ m2)” (opens the source at this quote in a new tab)
“Prior use of biologics (yes, no)” (opens the source at this quote in a new tab)
“Prior use of TYK 2 molecules (yes, no)” (opens the source at this quote in a new tab)